Business Context and Reporting Period
This Form 8-K Current Report from Silexion Therapeutics Corp (SLXN) covers events occurring on July 28 and July 29, 2025. The filing details the implementation of a 1-for-15 reverse share split approved by shareholders at the Annual General Meeting on July 14, 2025. The Company is an emerging growth company incorporated in the Cayman Islands with principal executive offices in Ramat-Gan, Israel.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes Versus Prior Period
- Reverse Share Split: Effective after the close of trading on July 28, 2025, the Company executed a 1-for-15 reverse share split. The number of issued and outstanding ordinary shares decreased proportionately.
- Share Capital and Par Value: The authorized share capital remains at $20,000, now consisting of 1,481,482 ordinary shares. The par value per share increased from $0.0009 to $0.0135.
- Warrant Adjustments: Warrants (SLXNW) were adjusted effective July 29, 2025. Each warrant is now exercisable for 1/15th of an ordinary share, and the exercise price increased fifteen-fold to $1,552.50 per whole post-split share.
- Trading Details: Ordinary shares began trading on a split-adjusted basis on July 29, 2025, under the ticker "SLXN" with a new CUSIP number (G1281K 130). Warrants continue to trade under "SLXNW" with CUSIP G1281K 114.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future performance, or specific risk factors beyond the mechanics of the share split. A notable operational detail is that the Company will not issue fractional shares upon warrant exercise; fractional shares will be rounded up to the nearest whole number at the broker level, subject to payment of the full exercise price for the rounded amount.
Key Facts for Investor Verification
- Verify the post-split share count of 1,481,482 authorized ordinary shares.
- Confirm the new warrant exercise price of $1,552.50 and the 1/15th share entitlement per warrant.
- Check the new CUSIP number for ordinary shares (G1281K 130) for trading and settlement purposes.
- Review the rounding policy for fractional shares resulting from warrant exercises to understand potential dilution or cash requirements.